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From CFTR biology toward combinatorial 
pharmacotherapy: expanded classification 
of cystic fibrosis mutations
ABSTRACT More than 2000 mutations in the cystic fibrosis transmembrane conductance 
regulator (CFTR) have been described that confer a range of molecular cell biological and 
functional phenotypes. Most of these mutations lead to compromised anion conductance at 
the apical plasma membrane of secretory epithelia and cause cystic fibrosis (CF) with variable 
disease severity. Based on the molecular phenotypic complexity of CFTR mutants and their 
susceptibility to pharmacotherapy, it has been recognized that mutations may impose combi-
natorial defects in CFTR channel biology. This notion led to the conclusion that the combina-
tion of pharmacotherapies addressing single defects (e.g., transcription, translation, folding, 
and/or gating) may show improved clinical benefit over available low-efficacy monotherapies. 
Indeed, recent phase 3 clinical trials combining ivacaftor (a gating potentiator) and luma-
caftor (a folding corrector) have proven efficacious in CF patients harboring the most com-
mon mutation (deletion of residue F508, ΔF508, or Phe508del). This drug combination was 
recently approved by the U.S. Food and Drug Administration for patients homozygous for 
ΔF508. Emerging studies of the structural, cell biological, and functional defects caused by 
rare mutations provide a new framework that reveals a mixture of deficiencies in different 
CFTR alleles. Establishment of a set of combinatorial categories of the previously defined 
basic defects in CF alleles will aid the design of even more efficacious therapeutic interven-
tions for CF patients.
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MUTATION CLASS–SPECIFIC PHARMACOTHERAPY
Defining the cellular and molecular pathology of CFTR mutations 
proved to be invaluable for development of small-molecule com-
pounds targeting the underlying defect(s) in CF. The fact that some 
CFTR variants carrying class III or IV mutations can be expressed at 
the apical membrane of secretory epithelia at a density similar to 
that of the wild-type protein, although they are functionally impaired 
(e.g., G551D), led to the development of gating potentiators that 
increase the open probability and thereby the PM chloride conduc-
tance (Yang et al., 2003). VX-770 (ivacaftor) is the first potentiator 
drug to be U.S. Food and Drug Administration approved for CF 
treatment; it directly targets the gating defect of the class III muta-
tion G551D-CFTR (Van Goor et al., 2009). This compound was de-
veloped by Vertex Pharmaceuticals in conjunction with Cystic Fibro-
sis Foundation Therapeutics, Inc. (CFFT), and shows remarkable 
clinical benefit in patients carrying the mutation in either one or two 
alleles (Van Goor et al., 2009; Accurso et al., 2010; Ramsey et al., 
2011). The approval of VX-770 was extended to eight additional 
class III mutations (G178R, S549N, S549R, G551S, G1244E, S1251N, 
S1255P, and G1349D) (Yu et al., 2012; Vertex, 2014a) and recently to 
the class IV mutation R117H (Vertex, 2014b).
The prototypical class II mutation, ΔF508-CFTR (Phe508del), elic-
its a complex folding defect that compromises both NBD1 stability 
and the channel’s cooperative domain assembly (Du and Lukacs, 
2009; Du et al., 2005; Mendoza et al., 2012; Rabeh et al., 2012). For 
many years, large-scale efforts have been under way to isolate cor-
rectors that act as pharmacological chaperones by directly binding 
to and promoting the biogenesis of class II CFTR mutations. The 
most promising corrector compound at present, VX-809 (luma-
caftor), partially reverts the ΔF508-CFTR functional expression 
INTRODUCTION
Cystic fibrosis (CF), caused by mutations in the cystic fibrosis trans-
membrane conductance regulator (CFTR), is characterized by a mul-
tiorgan pathology affecting the upper and lower airway, gastrointes-
tinal and reproductive tracts, and endocrine system (Riordan et al., 
1989; Collins, 1992; Rowe et al., 2005; Cutting, 2015). CF is one of 
the most common lethal autosomal-recessive diseases, with a prev-
alence of one in 3500 in the United States and one in 2500 in the 
European Union (Farrell, 2008; Pettit and Fellner, 2014). Lack of 
functional CFTR expression at the apical membrane of secretory 
epithelia results in defective Cl− and bicarbonate secretion, coupled 
to enhanced Na+ absorption and mucus secretion, which in airway 
epithelia leads to dehydration and acidification of the airway surface 
liquid (Tarran et al., 2001; Chen et al., 2010; Derichs et al., 2011; 
Pezzulo et al., 2012). As a consequence, impaired mucociliary clear-
ance provokes recurrent infection and uncontrolled inflammation 
culminating in lung damage, which is the primary cause of morbidity 
and mortality in CF (Ratjen and Doring, 2003; Boucher, 2007; Stoltz 
et al., 2015). CFTR is member of the ATP-binding cassette (ABC) 
subfamily C (ABCC7) (Kerr, 2002). It consists of two homologous 
halves, each containing a hexa-helical membrane-spanning domain 
(MSD1 and MSD2) and a nucleotide-binding domain (NBD1 and 
NBD2) that are connected by an unstructured regulatory domain 
(Riordan, 1993; Riordan et al., 1989).
BIOLOGY OF CFTR MUTATION: TRADITIONAL 
CLASSIFICATION
CF is caused by ∼2000 mutations in the CFTR gene with a wide range 
of disease severity (www.genet.sickkids.on.ca/home.html; www.cftr2 
.org; Sosnay et al., 2013), which is further influenced by modifier 
genes (Collaco and Cutting, 2008; Cutting, 2010) and by the environ-
mental and socioeconomic status of patients (Schechter et al., 2001; 
Barr et al., 2011; Taylor-Robinson et al., 2014; Kopp et al., 2015). The 
first classification of CF mutations into four classes according to their 
primary biological defect was proposed by Welsh and Smith in a land-
mark paper (Welsh and Smith, 1993). Currently, six major classes are 
distinguished (Rowe et al., 2005; Zielenski and Tsui, 1995) (Figure 1).
Class I encompasses frameshift, splicing, or nonsense mutations 
that introduce premature termination codons (PTC), resulting in se-
verely reduced or absent CFTR expression.
Class II mutations lead to misfolding, premature degradation by 
the endoplasmic reticulum (ER) quality-control system, and impaired 
protein biogenesis, severely reducing the number of CFTR mole-
cules that reach the cell surface.
Class III mutations impair the regulation of the CFTR channel, 
resulting in abnormal gating characterized by a reduced open 
probability.
Class IV mutations alter the channel conductance by impeding 
the ion conduction pore, leading to a reduced unitary conductance 
(Sheppard et al., 1993; Hammerle et al., 2001).
Class V mutations do not change the conformation of the protein 
but alter its abundance by introducing promoter or splicing abnor-
malities (Highsmith et al., 1994, 1997; Zielenski and Tsui, 1995).
Class VI mutations destabilize the channel in post-ER compart-
ments and/or at the plasma membrane (PM), by reducing its confor-
mational stability (Haardt et al., 1999) and/or generating additional 
internalization signals (Silvis et al., 2003). This results in accelerated 
PM turnover and reduced apical PM expression (Haardt et al., 1999; 
Silvis et al., 2003).
For many of the identified mutations, the disease liability is un-
known, but efforts are under way to assess their functional conse-
quence and clinical severity (www.cftr2.org; Sosnay et al., 2013).
FIGURE 1: Traditional classification of CF mutations based on their 
cellular phenotype. Class I: protein synthesis defect; class II: 
maturation defect; class III: gating defect; class IV: conductance 
defect; class V: reduced quantity; and class VI: reduced stability. ER, 
endoplasmic reticulum; TGN, trans-Golgi network.
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most common mutant has multiple defects that extend beyond 
the features of a class II mutation.
 – W1282X: This PTC represents a class I mutation, though recent 
studies suggest a more complex phenotype. First, the level of 
the W1282X transcript is reduced by nonsense-mediated RNA 
decay (Hamosh et al., 1992; Linde et al., 2007). Second, the PTC 
deletes part of the NBD2, which likely compromises NBD1-
NBD2 dimerization and W1282X-CFTR folding and activity. 
Moreover, if the primary defect is corrected either with spontane-
ous or drug-induced read-through, some of the fully translated 
channel will contain nonconservative amino acid substitutions. 
These missense mutations may cause structural defects (class II 
characteristic), as suggested by the phenotype of CF patients 
with a missense mutation at the W1282 residue (Faucz et al., 
2007; Ivaschenko et al., 1993; Visca et al., 2008), as well as a gat-
ing defect (class III characteristic), which can be inferred based 
on W1282X-CFTR channel activation after exposure to VX-770 
(Xue et al., 2014).
 – P67L: P67L is a mild class II mutation that results in attenuated 
CFTR biogenesis, as indicated by the reduced ratio between 
post-ER complex–glycosylated (band C) and ER-resident core-
glycosylated protein (band B) (Ren et al., 2013; Sosnay et al., 
2013; Van Goor et al., 2014). Treatment with the corrector VX-
809 increases the abundance of the complex-glycosylated form 
and PM density to nearly the level of WT-CFTR (Ren et al., 2013; 
Veit et al., 2014). However, the mutant channel is also sensitive in 
vitro to potentiator treatment (a class III characteristic), both in 
the presence and absence of corrector (Van Goor et al., 2014; 
Veit et al., 2014). Accordingly, treatment with VX-770 amelio-
rated the CF lung disease in a heterozygous P67L/ΔF508 patient 
(Yousef et al., 2015).
 – R117H: This mutation in conjunction with the 5T variant in the 
polythymidine tract in intron 8 was originally categorized as a 
class IV mutation, but it also exhibits a gating defect (class III trait) 
that, at least in part, can be rectified by VX-770 treatment (Shep-
pard et al., 1993; Van Goor et al., 2014). The R117H mutation 
also results in reduced complex-glycosylated CFTR expression, 
which is a class II characteristic (Fanen et al., 1997; Sheppard 
et al., 1993). This potentially explains the limited success of VX-
770 treatment in patients carrying this mutation (Char et al., 
2014; Moss et al., 2015).
AN EXPANDED CLASSIFICATION OF MUTANT 
CFTR BIOLOGY
We propose a modification of the current classification scheme, 
which would entail permutations of the traditional class I–VI CF mu-
tations. This expanded classification of the major mechanistic cate-
gories (Welsh and Smith, 1993; Zielenski, 2000; Rowe et al., 2005) 
accommodates the unusually complex, combinatorial molecular/
cellular phenotypes of CF alleles. It consists of 31 possible classes of 
mutations, including the original classes I, II, III/IV, V, and VI, as well 
as their 26 combinations, as depicted in the Venn diagram shown in 
Figure 2. For the sake of simplicity, class III and IV mutations, repre-
senting functional (gating and conductance, respectively) defects, 
are combined. For example, according to the expanded classifica-
tion, G551D will be designated as a class III mutation as before 
(Welsh and Smith, 1993), while ΔF508 will be classified as class II–III–
VI, W1282X as class I–II–III–VI, P67L as class II–III, and R117H as class 
II–III/IV, reflecting the composite defects in mutant CFTR biology 
(Figure 2 and Table 1).
defect by stabilizing the NBD1-MSD1/2 interface (Farinha et al., 
2013; Loo et al., 2013; Okiyoneda et al., 2013; Ren et al., 2013), 
leading to a marked correction from 3 to 15% of wild-type channel 
activity in vitro (Van Goor et al., 2011). A clinical trial, however, failed 
to observe significant clinical benefit in homozygous ΔF508-CFTR 
patients (Clancy et al., 2012). Acute addition of VX-770 to VX-
809-corrected ΔF508-CFTR doubled the PM activity in vitro (Van 
Goor et al., 2011), and the combination therapy showed modest but 
significant clinical improvement (Boyle et al., 2014; Wainwright 
et al., 2015). Based on these results, the combination treatment has 
been approved for CF patients 12 years and older with two copies 
of the ΔF508 mutation (Vertex, 2015). Other class II mutations that 
can be corrected by VX-809 in vitro include E56K, P67L, E92K, 
R170G, L206W, V232D, F508G, and A561E (Caldwell et al., 2011; 
Okiyoneda et al., 2013; Ren et al., 2013; Veit et al., 2014; Awatade 
et al., 2015).
Ribosomal read-through allows synthesis of full-length CFTR car-
rying class I mutations. To this end, ataluren (PTC124) was devel-
oped as a drug that promotes near-cognate aminoacyl-tRNA incor-
poration at PTCs (Lentini et al., 2014; Welch et al., 2007). Ataluren 
partially restores G542X-CFTR (class I) expression in a mouse model 
and modestly corrects CFTR function in nasal epithelia in patients 
with class I mutations (Du et al., 2008; Sermet-Gaudelus et al., 2010; 
Wilschanski et al., 2011). In a recent phase 3 clinical trial, however, 
ataluren treatment failed to produce significant clinical benefit, per-
haps due to an adverse drug–drug interaction with tobramycin, 
which is a commonly administered, inhaled antibiotic used to treat 
lung infections in CF patients (Kerem et al., 2014).
LIMITATIONS OF CF MUTATION CLASSIFICATION
The efficacy of available monotherapies for some mutant alleles, 
which have been designated as class I, class II, or class III/IV muta-
tions, is currently limited. This could be partly explained by the 
pleiotropic molecular defects caused by single mutations. Thus 
comprehensive mapping of the multiple molecular defects caused 
by a single or combination of mutant alleles could offer consider-
able advantage for improving therapeutic interventions and for fu-
ture development of drug combinations. In the following list, we 
present a subset of mutations that display combinatorial molecular 
defects.
 – ΔF508: The most prevalent class II mutation impairs CFTR con-
formational maturation and leads to its targeting for premature 
ER-associated degradation (Cheng et al., 1990; Cyr, 2005; Kim 
and Skach, 2012; Lukacs et al., 1994). However, ΔF508-CFTR 
molecules that either constitutively or following rescue proce-
dures escape the ER quality control and accumulate at the PM of 
airway epithelia exhibit a channel-gating defect, which is a hall-
mark of class III mutations (Dalemans et al., 1991), as well as ac-
celerated turnover in post ER compartments and at the PM, a 
class VI mutation characteristic (Lukacs et al., 1993). Unless the 
folding and conformational dynamics of the rescued ΔF508-
CFTR are fully restored to that of the wild-type protein by phar-
macological treatment, this mutation remains partially defective 
and requires correction of its gating and/or peripheral stability 
defect. Rescue of the gating defect can be achieved with poten-
tiators (e.g., VX-770) (Van Goor et al., 2009). Peripheral stabiliza-
tion of the ΔF508-CFTR could be attained by 1) the peptide in-
hibitor iCAL36 (Cushing et al., 2010), 2) preventing post-Golgi 
ubiquitination (Fu et al., 2015; Okiyoneda et al., 2010), 3) restor-
ing autophagosome formation (Luciani et al., 2012), or 4) modu-
lating cellular protein homeostasis (Hutt et al., 2010). Thus the 
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Refined  
classification Mutation I II III/IV V VI Model Reference
I–II–III–VI W1282X X1,2,3 X2,5 X2,4,5 X5 1HNE
2HBE
3CFBE
4CFBE
5CFBE
1Hamosh et al., 1992
2Cyr lab, unpublisheda
3Frizzell lab, unpublishedb
4Xue et al., 2014
5Lukacs lab, unpublishedc
II–III M1V X6 X6 6FRT 6 Van Goor et al., 2014
II–III E56K X5,6 X6 5CFBEd
6FRT
5Lukacs lab, unpublished
6Van Goor et al., 2014
II–III P67L X3,6,7,8,9,10 X6,7,10 3CFBE
6FRT
7CFBE
8Hek293
9HeLa
10FRT
3Frizzell lab, unpublished
6Van Goor et al., 2014
7Veit et al., 2014
8Ren et al., 2013
9Sosnay et al., 2013
10Sorscher lab, unpublishede
II–III R74W X6 X6 6FRT 6Van Goor et al., 2014
II-III E92K X3,5,6,8,16 X5 3CFBE
5CFBE
6FRT
8HEK293
16HEK293
3Frizzell lab, unpublished
5Lukacs lab, unpublished
6Van Goor et al., 2014
8Ren et al., 2013
16Brodsky lab, unpublished
II–III P99L X11 X11 11HeLa 11Sheppard et al., 1996
II–III D110H X6 X6 6FRT 6Van Goor et al., 2014
II–III R117C X6 X6 6FRT 6Van Goor et al., 2014
II–III R117H X2,3,12,13 X2,6,12 2HBE
3CFBE
6FRT
12FRT, HeLa
13HeLa
2Cyr lab, unpublished
3Frizzell lab, unpublished
6Van Goor et al., 2014
12Sheppard et al., 1993
13Fanen et al., 1997
FIGURE 2: Refined classification of CF mutations accounting for complex phenotypes of major 
CFTR cellular defects. The Venn diagram indicates all combinations of mutation classes with 
selected examples. Possible combinations without identified mutation are indicated in gray.
A recent study by Vertex Pharmaceuti-
cals successfully demonstrated that 24 of 54 
tested missensse mutations display both a 
processing (class II) and gating (class III) de-
fect in the Fischer rat thyroid epithelial ex-
pression system (Van Goor et al., 2014). 
Characterization of several rare CF muta-
tions is ongoing in laboratories of the CFTR2 
Consortium, the CFTR Folding Consortium, 
CFFT, Vertex Pharmaceuticals, and many 
others (Caldwell et al., 2011; Yu et al., 2012; 
Sosnay et al., 2013; Harness-Brumley et al., 
2014; Hong et al., 2014; Van Goor et al., 
2014; Wang et al., 2014; Awatade et al., 
2015). This work will likely provide further 
examples of combinatorial mechanistic de-
fects exhibited by CF mutants.
THERAPEUTIC SUSCEPTIBILITY OF 
CF MUTATIONS WITH COMPLEX 
BIOLOGICAL DEFECTS
In-depth analysis of the biology of CF mu-
tants distinguishes them according to their 
complex molecular pathology and suggests 
drug combinations for treatment of differ-
ent patient populations. This process, called 
TABLE 1: Examples for CF mutations with complex or classical cellular phenotypes. 
 Continues
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Refined  
classification Mutation I II III/IV V VI Model Reference
II–III R170G X7,14 X7 7CFBE
14BHK
7Veit et al., 2014
14Okiyoneda et al., 2013
II–III E193K X5 X5,6 5CFBE
6FRTf
5Lukacs lab, unpublished
6Van Goor et al., 2014
II–III P205S X11 X11 11HeLa 11Sheppard et al., 1996
II–III L206W X5,6,8 X5,6 5CFBE
6FRT
8HEK293
5Lukacs lab, unpublished
6Van Goor et al., 2014
8Ren et al., 2013
II–III V232D X15 X15 15HEK293 15Caldwell et al., 2011
II–III R334W X2,3,5 X2,5,6,12 2COS-7
3CFBE
5CFBE
6FRTf
12HeLa
2Cyr lab, unpublished
3Frizzell lab, unpublished
5 Lukacs lab, unpublished
6Van Goor et al., 2014
12Sheppard et al., 1993
II–III I336K X6 X6 6FRT 6Van Goor et al., 2014
II–III T338I X5,6 X5,6 5CFBE
6FRT
5Lukacs lab, unpublished
6Van Goor et al., 2014
II–III S341P X5,6 X5,6 5CFBE
6FRT
5Lukacs lab, unpublished
6Van Goor et al., 2014
II–III A455E X3,6,16, 17 X6 3CFBE
6FRT
16HEK293
17FRT, HeLad
3Frizzell lab, unpublished
6Van Goor et al., 2014
16Brodsky lab, unpublishedg
17Sheppard et al., 1995
II–III S549R X3,5,18 X5,18 3CFBE
5CFBE
15FRT
3Frizzell lab, unpublished
5Lukacs lab, unpublished
18Yu et al., 2012
II–III D579G X5,6 X5,6 5CFBE
6FRT
5Lukacs lab, unpublished
6Van Goor et al., 2014
II–III R668C X6 X6 6FRT 6Van Goor et al., 2014
II–III L927P X6 X6 6FRT 6Van Goor et al., 2014
II–III S945L X6 X6 6FRT 6Van Goor et al., 2014
II–III S977F X6 X6 6FRT 6 Van Goor et al., 2014
II–III L997F X6 X6 6FRT 6Van Goor et al., 2014
II–III H1054D X6 X6 6FRT 6Van Goor et al., 2014
II–III R1066H X6 X6 6FRT 6Van Goor et al., 2014
II–III A1067T X6 X6 6FRT 6Van Goor et al., 2014
II–III R1070Q X6 X6 6FRT 6Van Goor et al., 2014
II–III R1070W X6,14 X6 6FRT
14BHK
6Van Goor et al., 2014
14Okiyoneda et al., 2013
II–III F1074L X6 X6 6FRT 6Van Goor et al., 2014
II–III D1270N X6 X6 6FRT 6Van Goor et al., 2014
II–VI S492F X3,5,6 X5 3CFBE
5CFBE
6FRT
3Frizzell lab, unpublished
5Lukacs lab, unpublished
6Van Goor et al., 2014
II–III–VI R347P X3,5,6 X5,6,12 X5 3CFBE
5CFBE
6FRT
12HeLa
3Frizzell lab, unpublished
5Lukacs lab, unpublished
6Van Goor et al., 2014
12Sheppard et al., 1993
II–III–VI ΔF508 X19 X20 X21 19COS
20Vero
21CHO
19Cheng et al., 1990
20Dalemans et al., 1991
21Lukacs et al., 1993
TABLE 1: Examples for CF mutations with complex or classical cellular phenotypes. 
 Continues
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Refined  
classification Mutation I II III/IV V VI Model Reference
II–III–VI A561E X6,22,23 X23 X23 6FRTd
22HBEd
23BHK
6Van Goor et al., 2014
22Awatade et al., 2015
23Wang et al., 2014
II–III–VI L1077P X3,6,16,24 X24 X24 3CFBE
6FRT
16HEK293
24CHO
3Frizzell lab, unpublished
6Van Goor et al., 2014
16Brodsky lab, unpublished
24Sheppard lab, unpublishedh
II–III–VI N1303K X2,3,5,6,16,22,24 X24 X5 2HBE
3CFBE
5CFBE
6FRT
16HEK293
22HBE
24CHOi
2Cyr lab, unpublished
3Frizzell lab, unpublished
5Lukacs lab, unpublished
6Van Goor et al., 2014
16Brodsky lab, unpublished
22Awatade et al., 2015
24Sheppard lab, unpublished
III–VI Q1411X X25 X26 25BHK
26Cos, BHK
25Gentzsch et al., 2002
26Haardt et al., 1999
II A46D X6 6FRT 6Van Goor et al., 2014
II G85E X3,6,16,24 3CFBE
6FRT
16HEK293
24CHO
3Frizzell lab, unpublished
6Van Goor et al., 2014
16Brodsky lab, unpublished
24Sheppard lab, unpublished
III R352Q X5,6 5CFBE
6FRTf
5Lukacs lab, unpublished
6Van Goor et al., 2014
II L467P X6 6FRT 6Van Goor et al., 2014
II V520F X3,6,16 3CFBE
6FRT
16HEK293
3Frizzell lab, unpublished
6Van Goor et al., 2014
16Brodsky lab, unpublished
II A559T X6 6FRT 6Van Goor et al., 2014
II R560S X6 6FRT 6Van Goor et al., 2014
II R560T X3,6,16 3CFBE
6FRT
16HEK293
3Frizzell lab, unpublished
6Van Goor et al., 2014
16Brodsky lab, unpublished
II R560K X3 3CFBE 3Frizzell lab, unpublished
II Y569D X6 6FRT 6Van Goor et al., 2014
II D614G X3 3CFBE 3Frizzell lab, unpublished
II L1065P X3,6 3CFBE
6FRT
3Frizzell lab, unpublished
6Van Goor et al., 2014
II R1066C X3,6 3CFBE
6FRT
3Frizzell lab, unpublished
6Van Goor et al., 2014
II R1066M X6 6FRT 6Van Goor et al., 2014
II H1085R X6 6FRT 6Van Goor et al., 2014
II M1101K X6 6FRT 6Van Goor et al., 2014
III D110E X6 6FRT 6Van Goor et al., 2014
III G178R X18 18FRT 18Yu et al., 2012
III R347H X6,7 6FRT
7CFBE
6Van Goor et al., 2014
7Veit et al., 2014
III S549N X18 18FRT 18Yu et al., 2012
III G551D X27, 28 27CHO
28L
27Bompadre et al., 2007
28Yang et al., 1993
III G551S X18 18FRT 18Yu et al., 2012
TABLE 1: Examples for CF mutations with complex or classical cellular phenotypes. 
 Continues
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Refined  
classification Mutation I II III/IV V VI Model Reference
III F1052V X6 6FRT 6Van Goor et al., 2014
III K1060T X6 6FRT 6Van Goor et al., 2014
III D1152H X6 6FRT 6Van Goor et al., 2014
III S1235R X6 6FRT 6Van Goor et al., 2014
III G1244E X18 18FRT 18Yu et al., 2012
III S1251N X18 18FRT 18Yu et al., 2012
III S1255P X18 18FRT 18Yu et al., 2012
III G1349D X18,27 18FRT
27CHO
18Yu et al., 2012
27Bompadre et al., 2007
Superscript numbers refer to references in far-right column.
aS.A.H. and D.M.C., unpublished observations
bK.W.P. and R.A.F., unpublished observations.
cR.G.A., H.Xu, and G.L.L., unpublished observations.
dDoes not exhibit a gating or conductance defect in this cell model.
eJ.S.H. and E.J.S., unpublished observations.
fDoes not exhibit a biogenesis defect in this cell model.
gA.N.C. and J.L.B., unpublished observations.
hZ.C. and D.N.S., unpublished observations.
iDoes not exhibit a peripheral stability defect in this cell model.
TABLE 1: Examples for CF mutations with complex or classical cellular phenotypes. Continued
“theratyping” (Cutting, 2015), will pave the way to personalized 
medicine in CF. However, reliable prediction of the responsiveness 
of a mutant phenotype to pharmacotherapy could be challenging 
and is dependent on the cellular model system (Pedemonte et al., 
2010).
Emerging evidence also suggests that the efficacy of approved 
and preclinical drugs may vary with different mutations within the 
same class. For example, while nearly complete processing correc-
tion of P67L- and R170G-CFTR (class II) was achieved with VX-809 
treatment (Okiyoneda et al., 2013; Ren et al., 2013; Veit et al., 2014), 
VX-809 only partially reversed the folding defect of some other class 
II mutants; for example, N1303K and ΔF508 (Okiyoneda et al., 2013; 
Awatade et al., 2015). This differential susceptibility to correction is 
attributed to the nature of the primary folding/structural defect. Ac-
cording to one hypothesis, robust folding correction of ΔF508-CFTR 
requires corrector combinations to avert its NBD1-MSD1/2 interface 
and NBD1 stability defects (Mendoza et al., 2012; Rabeh et al., 
2012; He et al., 2013; Okiyoneda et al., 2013). The N1303K muta-
tion in NBD2 was not rescued by VX-809, and only modest process-
ing was observed by targeting both the NBD1/MSDs and NBD2 
interfaces with C4 and C18 (a VX-809 analogue) (Okiyoneda et al., 
2013; Rapino et al., 2015).
Some of the class III mutations also respond differently to the 
gating potentiator VX-770. Although R347H- and T338I-CFTR cause 
severe functional defects with no or modest loss of protein expres-
sion, only R347H-CFTR is potentiated by VX-770 to near wild type–
like conductance (Van Goor et al., 2014). Likewise, the P5 potentia-
tor activates ΔF508-CFTR, but it has no effect on G551D-CFTR 
chloride permeation (Yang et al., 2003). Thus identification of muta-
tion-specific novel potentiators or their combinations may further 
optimize channel rescue for specific class III/IV mutations. Additive 
enhancement of G551D-CFTR activity by the combination of the po-
tentiators genistein and curcumin supports the feasibility of combin-
ing potentiators (Yu et al., 2011). Likewise, we envision that muta-
tion-specific read-through drugs will ultimately need to be combined 
with other correctors and potentiators, based on the pleiotropic 
defects associated with this class of mutations (as illustrated for 
W1282X above).
CONCLUDING REMARKS
The ultimate goal of theratyping is to achieve optimal correction of 
a specific mutant defect by selecting the most efficacious CFTR 
modulator(s), including correctors(s), potentiator(s), and/or read-
through drugs, or a combination of these drugs. Based on accumu-
lating observations, however, mechanistic subdivisions of some of 
the major classes of mutations (classes I, II, and III) may be necessary 
to further improve the success of drug-selection strategies. This will 
facilitate the theratyping of CF alleles and their combinations and 
expedite the identification and approval process for combination 
therapies. Theratyping has already proven successful in identifying 
class III mutations that are responsive to VX-770 (Yu et al., 2012), 
leading to the approval of this drug for eight rare mutations besides 
G551D (Vertex, 2014a). In fact, the results of large-scale theratyping 
could be overlaid as a third dimension on the Venn diagram pre-
sented in Figure 2.
Thus, during the 22 years following the initial classification of CF 
mutations (Welsh and Smith, 1993), our understanding of the mole-
cular complexity of CF alleles has evolved remarkably, establishing 
the need for an advanced mutation classification scheme in con-
junction with personalized CF therapy.
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